Highlights•Rising cost of innovative pharmaceuticals may affect access.•Uptake of managed entry agreements/ arrangements are slow.•Challenges in implementing the schemes needs to be addressed to improve access.•Engagement of stakeholders will bring more light to the challenges faced.